| | |
| Clinical data | |
|---|---|
| Trade names | Dalmarelin, Ovucron, Reproreline |
| Other names | H-Pyr-His-Trp-Ser-Tyr-D-Gly(tBu)-Leu-Arg-Pro-NHEt; XHWSYXLRP |
| Routes of administration | Injection |
| Drug class | GnRH agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.224.787 |
| Chemical and physical data | |
| Formula | C59H84N16O12 |
| Molar mass | 1209.421 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lecirelin, sold under the brand names Dalmarelin, Ovucron, and Reproreline, is a short-acting gonadotropin-releasing hormone agonist (GnRH agonist) medication which is used in veterinary medicine in Europe and Israel. [1] [2] [3] [4] It is a GnRH analogue and a synthetic peptide, specifically a nonapeptide. [1] [2] [3] The drug was introduced for veterinary use by 2000. [5] It is used in form of the acetate salt. [6]